Speciale Alfina A, Ellerington Ruth, Goedert Thomas, Rinaldi Carlo
Department of Paediatrics, University of Oxford, Oxford OX1 3QX, UK.
J Pers Med. 2020 Oct 17;10(4):178. doi: 10.3390/jpm10040178.
Advances in knowledge resulting from the sequencing of the human genome, coupled with technological developments and a deeper understanding of disease mechanisms of pathogenesis are paving the way for a growing role of precision medicine in the treatment of a number of human conditions. The goal of precision medicine is to identify and deliver effective therapeutic approaches based on patients' genetic, environmental, and lifestyle factors. With the exception of cancer, neurological diseases provide the most promising opportunity to achieve treatment personalisation, mainly because of accelerated progress in gene discovery, deep clinical phenotyping, and biomarker availability. Developing reproducible, predictable and reliable disease models will be key to the rapid delivery of the anticipated benefits of precision medicine. Here we summarize the current state of the art of preclinical models for neuromuscular diseases, with particular focus on their use and limitations to predict safety and efficacy treatment outcomes in clinical trials.
人类基因组测序带来的知识进步,加上技术发展以及对疾病发病机制的更深入理解,为精准医学在多种人类疾病治疗中发挥越来越重要的作用铺平了道路。精准医学的目标是基于患者的基因、环境和生活方式因素,确定并提供有效的治疗方法。除癌症外,神经疾病为实现个性化治疗提供了最有前景的机会,这主要得益于基因发现、深入临床表型分析和生物标志物可用性方面的加速进展。开发可重复、可预测且可靠的疾病模型,将是迅速实现精准医学预期效益的关键。在此,我们总结了神经肌肉疾病临床前模型的当前技术水平,特别关注其在预测临床试验中治疗安全性和疗效结果方面的应用及局限性。